



PATENT
Docket No.: 21829/31 (EBC-002)

1638
AUG 30 2001
RECEIVED
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :	Wei et al.)	Examiner:
Serial No. :	09/412,100)	A. Nelson
Cnfrm. No. :	9211)	Art Unit:
Filed :	October 4, 1999)	1638
For :	HYPERSENSITIVE RESPONSE ELICITOR)	
	FRAGMENTS WHICH ARE ACTIVE BUT)	
	DO NOT ELICIT A HYPERSENSITIVE)	
	RESPONSE)	

Assistant Commissioner for Patents
Washington, D.C. 20231

Box:

Dear Sir:

Transmitted herewith in the above-identified application are:

- ☒ Response to Restriction Requirement (1 page);
 - ☒ Request for Two-Month Extension of Time (1 page) (in duplicate);
 - ☒ Check in the amount of **\$195.00** to cover the extension of time fee; and
 - ☒ A self-addressed, prepaid postcard acknowledging receipt.
- ☒ The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 14-1138.

A duplicate copy of this sheet is enclosed.

Date: August 24, 2001

Michael L. Goldman
Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (716) 263-1304
Facsimile: (716) 263-1600

R516477.1

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on the date below.	
8/24/01	<u>Jo Ann Whalen</u>
Date	Jo Ann Whalen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kathryn S. Prickett, et al.

Serial No.: 09/561,226

Filed: April 28, 2000

For: MODIFIED EXENDINS AND
EXENDIN AGONISTS

Group Art Unit: ~~1646~~ 1653

Examiner: To be assigned

RECEIVED
TECH CENTER 1600/2900
01 SEP 18 PM 3:46

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed are the following documents:

- Statement Under 37 C.F.R. §1.821 (F);
- Sequence Listing in paper form;
- Sequence Listing in computer-readable form;
- Request for Approval of Drawing Correction Under 37 C.F.R. §1.121;
- Preliminary Amendment to Include Substitute Specification Under 37 C.F.R. 1.125(B);
- Two (2) sets of proposed Amended Drawings;

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

8/24/01
Date of Deposit

Edward O. Kreyse
Name of Person Mailing Paper
SK
Signature of Person Mailing Paper


- Substitute Specification (Clean and Amended versions);
- Grant of Power of Attorney; and
- Return Postcard.

The Commissioner is authorized to charge any additional fee required or to credit any overpayment to our Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 8/24/01

By: 
Edward O. Kreusser
Reg. No. 38,523

EOK:jxb

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130-2081
Telephone: (858) 720-2500
Facsimile: (858) 720-2555

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Prickett *et al.*

Serial No.: 09/561,226

Filed: April 28, 2000

For: MODIFIED EXENDINS AND
EXENDIN AGONISTS

) Group Art Unit: 1653
)
)
) Examiner: Not yet assigned
)
)
)
)
)
)

RECEIVED
TECH CENTER 1600/2900
01 SEP 18 PM 3:47

REQUEST FOR APPROVAL OF DRAWING CORRECTION
UNDER 37 C.F.R. § 1.121

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

Applicants respectfully request that the Examiner approve the drawing correction of Figures 1, 2, 3, and 4A-4J that were initially filed in the above-identified patent application. Applicants have amended Figures 1, 2, 4C, 4D, 4H, 4I and 4J only to include SEQ ID NOS. Applicants have amended Figures 3, 4A, 4B, 4E, 4F and 4G to add or correct SEQ ID NOS. Original drawings 3, 4A, 4B, 4E, 4F and 4G also had reference to "compound" numbers that are not fully recited in the specification. References to compound numbers in these drawings have therefore been deleted in these Figures as unnecessary, particularly since all compounds now have been assigned SEQ ID NOS. The text in the top left corner box of Figures 4A, 4E, 4F, and 4G has been amended from


CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

8/24/01

Date of Deposit

Edward O. Krensser
Name of Person Mailing Paper


Signature of Person Mailing Paper

"Amino Acid Position" to -SEQ ID NO.— for clarity. None of these changes adds new matter, and Applicants request that the Examiner approve the amendments to the drawings.

Applicants enclose herewith two copies of each sheet of revised drawings. The changes to the drawing are marked in red, indicating the proposed corrections to the drawings. Applicants will provide new drawings in compliance with 37 CFR §1.84 that include the changes upon approval by the Examiner. Applicants respectfully request that this Request for Approval of Drawing Correction under 37 C.F.R. §1.121 be approved.

No fees are believed due with this submission. However, if any fee is due, please charge the appropriate amount to Deposit Account No. .50-1273.

Respectfully submitted,

Dated: _____

8/24/01

By: _____

Edward O. Kreusser
Re. No. 38, 523

Brobeck Phleger & Harrison, LLP
12390 El Camino Real
San Diego, CA 92130
Writer's Direct Dial: (858) 720-2720

Figure 1

His	Ser	Asp	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5				10						15	
Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser
		20						25					30		
Ser	Gly	Ala	Pro	Pro	Pro	Ser-NH ₂	<u>[SEQ. ID. NO. 1]</u>								
		35													

Figure 2

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5				10						15	
Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser
		20						25					30		
Ser	Gly	Ala	Pro	Pro	Pro	Ser-NH ₂	<u>[SEQ. ID. NO. 2]</u>								
		35													